Re: What's the deal with Zenith?
in response to
by
posted on
Jun 22, 2023 03:30PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
And of course, this whole thing (as proposed by Don M.) is based on the premise that BOM2 will be a success so that Resverlogix will be able to pay its debt to Zenith and for Zenith C C to collect on the Resverlogix Royalty Preferred Shares.
Don sounded firm on this scenario, as a way of funding Resverlogix, BOM2 via Zenith et al. as if he can do it unilaterally without the approval of the Zenith Shareholders.
Koo